Updates in the Management of Clostridium Difficile for Adults

Kimberly E. Ng, PharmD, BCPS


US Pharmacist. 2019;44(4):HS9-HS12. 

In This Article


Vancomycin is a glycopeptide that inhibits bacterial cell wall synthesis by blocking glycopeptide polymerization through binding to the d-alanyl-d-alanine portion of the cell-wall precursor. Vancomycin is administered orally for treatment of CDI and is minimally systemically absorbed to achieve higher concentrations in the colon. Adverse effects of oral vancomycin include abdominal pain, dysgeusia, nausea, headache, flatulence, and peripheral edema.[6,7]